Prednisone

3 articles published between September 14, 2026 and October 6, 2026.

Covered in Science and Body.

WHAT THE STUDY ACTUALLY SAYS

A bispecific antibody joined first-line lymphoma chemo. Complete response hit 95%.

A single-arm phase 2 trial added glofitamab to pola-R-CHP in 41 people with newly diagnosed B-cell lymphoma. The best complete-response rate was 95%, cytokine release stayed grade 1, and no neurotoxicity was reported.

4 min read

THE DRUG DOCKET

A biologic helped polymyalgia patients taper steroids in a phase 3 trial

REPLENISH randomised 381 patients with relapsed polymyalgia rheumatica. Sustained remission at 52 weeks reached about 41% on secukinumab versus 20.4% on placebo. Novartis funded the trial.

4 min read

WHAT THE STUDY ACTUALLY SAYS

Adding immunoglobulin to steroids improved new-onset myositis in a small trial

A single-centre randomised trial found that three cycles of intravenous immunoglobulin on top of high-dose steroids improved muscle disease faster and further — in just 44 patients, at one Dutch hospital.

3 min read

This page indexes this newspaper’s reporting on Prednisone. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.